Anti-CD47 drugs help target the CD47 protein present on tumor cells, which acts as a "don't eat me" signal to the immune system's macrophages. By blocking this protein, anti-CD47 drugs help macrophages identify and eliminate cancer cells more effectively. These drugs have shown promising results in clinical trials for treating hematological as well as solid tumors. Given their novel mechanism of action to enhance cell phagocytosis, anti-CD47 drugs are increasingly being viewed as a complementary approach to other immunotherapies.
The Anti CD47 Drugs Market anti-CD47 drugs market is estimated to be valued at US$ 0.14 Bn in 2024 and is expected to exhibit a CAGR of 42% over the forecast period 2024-2031.
Key Takeaways
Key players analysis: Key players operating in the anti-CD47 drugs market are Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, and Forty Seven.
Key players operating in the anti-CD47 drugs are Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, and Forty Seven. Bristol Myers Squibb is developing anti-CD47 drug magrolimab in Phase 3 trials for myelodysplastic syndrome. ALX Oncology is testing evorpacept across multiple hematological and solid tumors in Phase 2 trials.
Growing demand: Increasing prevalence of various cancers and lack of effective treatment options have boosted the demand for novel drugs like anti-CD47 therapies. According to reports, global cancer incidence is expected to rise by over 50% in the next 20 years.
Technological advancement: Recent technological advances have allowed more selective targeting of CD47 proteins, improving the efficacy and safety profile of anti-CD47 drugs. Companies are developing next-gen anti-CD47 molecules through novel mechanisms like bispecific antibodies and ADCs.
Market Trends
Combination therapies: Given anti-CD47 drugs enhance phagocytosis, combining them with other treatment modalities like chemotherapy, targeted therapy and immune checkpoint inhibitors is gaining traction. Ongoing clinical studies are evaluating such combination regimens.
Early-stage pipeline: While key players are testing anti-CD47 drugs in late-stage trials, several small biotechs are exploring these molecules in early-phase studies across a wider range of hematological and solid tumors. This is expanding evaluation of anti-CD47 therapy to additional cancer types.
Market Opportunities
First FDA approvals: Bristol Myers Squibb's magrolimab and ALX Oncology's evorpacept are the furthest in development and have potential to become the first anti-CD47 drugs to receive regular approvals by 2024-2025 period.
Potential new indications: As clinical evidence grows, anti-CD47 drugs may gain approvals beyond hematological cancers in other difficult-to-treat solid tumors like non-small cell lung cancer and prostate cancer over the forecast period. This will accelerate revenue generation.
Impact Of COVID-19 On Anti CD47 Drugs Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Anti CD47 Drugs Market. During the initial phase of the pandemic, drug development efforts and clinical trial activities of pharma companies witnessed major disruptions due to lockdowns and supply chain issues. This led to delays in completing clinical trials and drug approvals for anti CD47 drugs within the anticipated timelines. The demand for anti CD47 drugs also reduced temporarily as priority shifted to developing therapies and vaccines for COVID-19. However, with relaxation in lockdown restrictions and resumption of clinical trials from mid-2020, the development process of new anti CD47 drugs resumed.
The pandemic has further increased focus on cancer immunotherapy due to its potential to boost immunity in patients. This is positively impacting research into anti CD47 drugs that can help enhance immune response against cancer cells. Pharma companies working in this domain are actively collaborating with research institutes to evaluate the efficacy of anti CD47 drugs in restoring immunity against both cancer and SARS-CoV-2 infection. If successful, these efforts may accelerate commercialization timelines for such drugs going forward. With increasing acceptance of digital healthcare solutions during the pandemic, virtual clinical trials are also supporting continued progress of anti CD47 therapy development.
Geographical Regions With Highest Value Concentration Of Anti CD47 Drugs Market
North America is currently the leading region accounting for the major share of the Anti CD47 Drugs Market value. The region is home to several global pharma players focusing on development of monoclonal antibodies and immunotherapy drugs for cancer treatment. Moreover, high healthcare expenditure, favorable reimbursement policies, and presence of advanced medical facilities are fueling research and clinical trials of anti CD47 drugs across the US and Canada.
Asia Pacific is projected to witness fastest growth in the Anti CD47 Drugs Market over the forecast period. This can be attributed to rising cancer incidence, growing healthcare investment, increasing number of clinical trial initiations, and presence of large patient pool in countries like China, Japan and India. Furthermore, expanding biotech industry, emerging pharmaceutical manufacturing capabilities, and strengthened regulations supporting clinical research are fueling anti CD47 drug development activities in Asia Pacific region.
Get more insights on this topic: https://www.trendingwebwire.com/anti-cd47-drugs-market-set-for-strong-growth-due-to-advancements-in-cancer-immunotherapy/
Author Bio
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
What Are The Key Data Covered In This Anti CD47 Drugs Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Anti CD47 Drugs 's growth between 2024 and 2031.
:- Accurate calculation of the size of the Anti CD47 Drugs and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Anti CD47 Drugs Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Anti CD47 Drugs vendors
FAQ’s
Q.1 What are the main factors influencing the Anti CD47 Drugs ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Anti CD47 Drugs companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Anti CD47 Drugs ’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment